In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...
New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in pediatric ICU utilization.
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...
The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...
RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...
RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...
Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...
Nirsevimab is also recommended for some younger children between ages 8 and 19 months, particularly those who are at an increased risk for RSV. The CDC recommends all adults ages 75 and older and ...